Results 301 to 310 of about 333,510 (359)

SMC4 Promotes Prostate Cancer Cell Proliferation and Metastasis via the Rheb/mTOR Pathway

open access: yesAdvanced Science, EarlyView.
Structural maintenance of chromosome protein 4 (SMC4) has been implicated in prostate cancer metastasis. Knockdown of SMC4 in RM1‐LM cells significantly attenuates proliferation, migration, and lung metastasis in vivo. Furthermore, SMC4 interacts with GLUT1 (Slc2a1), thereby enhancing glycolysis, ATP production, and activation of the Rheb/mTOR pathway.
Wei Zhang   +9 more
wiley   +1 more source

Identification of CD38high Monocyte as a Candidate Diagnostic Biomarker and Therapeutic Target for Sepsis

open access: yesAdvanced Science, EarlyView.
This study uncovers that CD38high monocytes discriminate sepsis and sterile inflammation and are associated with 28‐day mortality in bacterial sepsis. Targeting CD38 therapy reduces inflammatory response in monocytes and in sepsis mice model. Mechanistically, CD38‐HIF‐1α/glycolysis/MGO loop exacerbates sepsis‐induced immune dysregulation.
Ning Hua   +19 more
wiley   +1 more source

Efficient Generation of Megakaryocyte Progenitors and Platelets From HSPCs via JAK2/STAT3 Signaling

open access: yesAdvanced Science, EarlyView.
This research presents a novel strategy employing the VGM cocktail, which combines HES7 overexpression with HDAC inhibitor and GABA, to enhance platelet production from hematopoietic stem and progenitor cells by promoting megakaryocyte progenitor (MkP) generation.
Huicong Liu   +6 more
wiley   +1 more source

Autocrine GDF10 Inhibits Hepatic Stellate Cell Activation via BMPR2/ALK3 Receptor to Prevent Liver Fibrosis

open access: yesAdvanced Science, EarlyView.
Liver fibrosis is a growing global health burden with no specific treatment. HSC activation is the predominant driver of liver fibrogenesis and the current focus in antifibrotic drug discovery. This study identifies autocrine GDF10 activates BMPR2/ALK3‐SMAD1/5/8‐SMAD7 pathway to counteract the TGF‐β‐SMAD2/3 pathway in HSCs, thereby inhibiting HSC ...
Yinliang Zhang   +16 more
wiley   +1 more source

AKT1E17K‐Interacting lncRNA SVIL‐AS1 Promotes AKT1 Oncogenic Functions by Preferentially Blocking AKT1E17K Dephosphorylation

open access: yesAdvanced Science, EarlyView.
Wang et al. discover a novel lncRNA regulator of mutant oncoprotein which prevents AKT1E17K dephosphorylation. SVIL‐AS1 overexpression correlates with poor prognosis of breast cancer patients. It interacts with AKT1E17K protein and impedes PP2A holoenzyme from dephosphorylating AKT1 by blocking the binding of the regulatory subunit PPP2R2A to AKT1 ...
Jingyi Wang   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy